These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 29767739)
1. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. Garland SM; Pitisuttithum P; Ngan HYS; Cho CH; Lee CY; Chen CA; Yang YC; Chu TY; Twu NF; Samakoses R; Takeuchi Y; Cheung TH; Kim SC; Huang LM; Kim BG; Kim YT; Kim KH; Song YS; Lalwani S; Kang JH; Sakamoto M; Ryu HS; Bhatla N; Yoshikawa H; Ellison MC; Han SR; Moeller E; Murata S; Ritter M; Sawata M; Shields C; Walia A; Perez G; Luxembourg A J Infect Dis; 2018 Jun; 218(1):95-108. PubMed ID: 29767739 [TBL] [Abstract][Full Text] [Related]
2. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885 [TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572 [TBL] [Abstract][Full Text] [Related]
5. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582 [TBL] [Abstract][Full Text] [Related]
7. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A; N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011 [TBL] [Abstract][Full Text] [Related]
8. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Moreira ED; Giuliano AR; de Hoon J; Iversen OE; Joura EA; Restrepo J; Van Damme P; Vandermeulen C; Ellison MC; Krick A; Shields C; Heiles B; Luxembourg A Hum Vaccin Immunother; 2018 Feb; 14(2):396-403. PubMed ID: 29211620 [TBL] [Abstract][Full Text] [Related]
9. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Giuliano AR; Joura EA; Garland SM; Huh WK; Iversen OE; Kjaer SK; Ferenczy A; Kurman RJ; Ronnett BM; Stoler MH; Bautista OM; Moeller E; Ritter M; Shields C; Luxembourg A Gynecol Oncol; 2019 Jul; 154(1):110-117. PubMed ID: 30982556 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913 [TBL] [Abstract][Full Text] [Related]
11. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258 [TBL] [Abstract][Full Text] [Related]
12. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510 [TBL] [Abstract][Full Text] [Related]
13. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Van Damme P; Olsson SE; Block S; Castellsague X; Gray GE; Herrera T; Huang LM; Kim DS; Pitisuttithum P; Chen J; Christiano S; Maansson R; Moeller E; Sun X; Vuocolo S; Luxembourg A Pediatrics; 2015 Jul; 136(1):e28-39. PubMed ID: 26101366 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Mugo N; Ansah NA; Marino D; Saah A; Garner EI Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475 [TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Kosalaraksa P; Mehlsen J; Vesikari T; Forstén A; Helm K; Van Damme P; Joura EA; Ciprero K; Maansson R; Luxembourg A; Sobanjo-ter Meulen A Pediatr Infect Dis J; 2015 Jun; 34(6):627-34. PubMed ID: 25831420 [TBL] [Abstract][Full Text] [Related]
17. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the 9-valent HPV vaccine in men. Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial. Thiem VD; Quang ND; Tuan NH; Cheon K; Gallagher N; Luxembourg A; Group T; Badshah C Hum Vaccin Immunother; 2021 Jul; 17(7):1980-1985. PubMed ID: 33844623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]